Fair Value Measurements (Narrative) (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended		3 Months Ended		6 Months Ended	12 Months Ended		12 Months Ended			1 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013 Rising Pharmaceuticals Inc. [Member]	Mar. 31, 2013 Rising Pharmaceuticals Inc. [Member]	Jun. 30, 2013 Rising Pharmaceuticals Inc. [Member]	Jun. 30, 2013 Rising Pharmaceuticals Inc. [Member]	Jun. 30, 2012 Rising Pharmaceuticals Inc. [Member]	Jun. 30, 2013 Foreign Currency Contract [Member]	Jun. 30, 2012 Foreign Currency Contract [Member]	Jun. 30, 2011 Foreign Currency Contract [Member]	Mar. 31, 2011 Interest Rate Swap [Member] Cash Flow Hedging [Member]	Jun. 30, 2013 Interest Rate Swap [Member] Cash Flow Hedging [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount								$ 59,316			$ 20,000	$ 12,125
Unrealized gains (losses) on hedging activities								(160)	(560)	160
Derivative, expiration date											Dec. 31, 2015
Unrealized loss on interest rate swap	258
Contingent consideration at fair value			5,346		5,346	5,346	1,779
Contingent consideration, accrued interest expense						323
Business acquisition, additional contingent consideration accrued	$ 3,244	$ 761	$ 404	$ 2,840	$ 3,244